Evolution of Thromboelastography During Tranexamic Acid Treatment (TTRAP-Bleeding)

This is an interventional treatment trial for Hematological Malignancies Treated With Intensive Chemotherapy focused on measuring Tranexamic acid, bleeding, hematological malignancies, thrombocytopenia Read More

Inclusion Criteria:

• Patient affiliated to a social security regimen or beneficiary of the same
• Signed written informed consent form
• Confirmed diagnosis of a hematological malignancy and undergoing intensive chemotherapy
• Expected to experience hypoproliferative thrombocytopenia resulting in a platelet count of ≤10 G/L for ≥ 5 days

Exclusion Criteria:

• Pregnant women
• Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent
• Refractoriness to platelet transfusion or requirement for a specific type of platelet transfusion (ABO-compatible, plasma-free)
• Ongoing anticoagulant therapy or antiplatelet therapy at the time of enrolment
• Treatment with any pro-coagulant agent within 48 hours of enrolment, or enrolment in other trials involving platelet transfusions, platelet growth factors, or presentation of a known hypercoagulable state
• Diagnosis of arterial or venous thromboembolic disease within the previous year
• Patient experiencing a bleeding event WHO grade ≥ 2 within 7 days before inclusion
• contra-indications to tranexamic acid (allergy, history of seizures, creatinine clearance < 30 mL/min)
• Refusing participation